1. Home
  2. CRVS
  3. CRVS News

Latest Corvus Pharmaceuticals Inc. (CRVS) News on June 22, 2025

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
CRVS

GlobeNewswire

11 days ago

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

CRVS

MT Newswires

18 days ago

Corvus Pharmaceuticals Reports 'Clinically Meaningful' Itch Reduction in Latest Phase 1 Atopic Dermatitis Drug Trial Results

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
CRVS

GlobeNewswire

18 days ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
CRVS

GlobeNewswire

24 days ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

CRVS

MT Newswires

a month ago

Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating

Spotlight On Top Penny Stocks For May 2025
CRVS

Simply Wall St.

a month ago

Spotlight On Top Penny Stocks For May 2025

CRVS

MT Newswires

a month ago

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating

Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030?
CRVS

Insider Monkey

a month ago

Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030?

CRVS

MT Newswires

a month ago

Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket

CRVS

GuruFocus.com

a month ago

Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ...

CRVS

Associated Press Finance

a month ago

Corvus: Q1 Earnings Snapshot

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
CRVS

GlobeNewswire

a month ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
CRVS

GlobeNewswire

a month ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025
CRVS

GlobeNewswire

2 months ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires?
CRVS

Insider Monkey

2 months ago

Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires?

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors
CRVS

GlobeNewswire

2 months ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

CRVS

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Corvus Pharmaceuticals Inc Earnings Call

Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit
CRVS

Simply Wall St.

3 months ago

Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit

CRVS

MT Newswires

3 months ago

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating

CRVS

GuruFocus.com

3 months ago

Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

CRVS

Associated Press Finance

3 months ago

Corvus: Q4 Earnings Snapshot

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
CRVS

GlobeNewswire

3 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
CRVS

GlobeNewswire

3 months ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
CRVS

GlobeNewswire

3 months ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
CRVS

GlobeNewswire

3 months ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
CRVS

GlobeNewswire

3 months ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
CRVS

GlobeNewswire

5 months ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
CRVS

GlobeNewswire

5 months ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CRVS

GlobeNewswire

5 months ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn
CRVS

Simply Wall St.

5 months ago

We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
CRVS

Benzinga

6 months ago

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

CRVS

MT Newswires

6 months ago

Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
CRVS

GlobeNewswire

6 months ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Tessera gets sickle cell funding; Corvus shares slide on eczema data
CRVS

BioPharma Dive

6 months ago

Tessera gets sickle cell funding; Corvus shares slide on eczema data

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
CRVS

GlobeNewswire

6 months ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16%
CRVS

Simply Wall St.

6 months ago

Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16%

CRVS

MT Newswires

7 months ago

Corvus Pharmaceuticals Says Published Soquelitinib Data Highlights Novel Approach to Immunotherapy

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
CRVS

GlobeNewswire

7 months ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
CRVS

GlobeNewswire

7 months ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

An Intrinsic Calculation For Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Suggests It's 41% Undervalued
CRVS

Simply Wall St.

7 months ago

An Intrinsic Calculation For Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Suggests It's 41% Undervalued

CRVS

GuruFocus.com

7 months ago

Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ...

CRVS

Associated Press Finance

7 months ago

Corvus: Q3 Earnings Snapshot

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
CRVS

GlobeNewswire

7 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
CRVS

GlobeNewswire

7 months ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024
CRVS

GlobeNewswire

8 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

CRVS

MT Newswires

8 months ago

Corvus Pharmaceuticals Shares Rise After Mizuho Upgrade

Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment
CRVS

Simply Wall St.

8 months ago

Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
CRVS

Zacks

9 months ago

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
CRVS

GlobeNewswire

9 months ago

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CRVS

GlobeNewswire

10 months ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CRVS

Associated Press Finance

10 months ago

Corvus: Q2 Earnings Snapshot

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
CRVS

GlobeNewswire

10 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases
CRVS

GlobeNewswire

a year ago

Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases

Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) stock price dropped 12% last week; retail investors would not be happy
CRVS

Simply Wall St.

a year ago

Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) stock price dropped 12% last week; retail investors would not be happy

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
CRVS

GOBankingRates

a year ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

Bumrah delivers as India beat Pakistan in low-scoring thriller
CRVS

AFP

a year ago

Bumrah delivers as India beat Pakistan in low-scoring thriller

Italy beat Bosnia in final Euros warm-up
CRVS

AFP

a year ago

Italy beat Bosnia in final Euros warm-up

Trump loyalists proud to support 'felon' at Las Vegas rally
CRVS

AFP

a year ago

Trump loyalists proud to support 'felon' at Las Vegas rally

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
CRVS

Business Insider

a year ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women
CRVS

Insider Monkey

a year ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase
CRVS

Reuters

a year ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

CRVS

Insider Monkey

a year ago

Best Date Night Fragrance in 2024

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

13 Penny Stocks with Insider Buying in 2024
CRVS

Insider Monkey

a year ago

13 Penny Stocks with Insider Buying in 2024

Insider Spends US$1m Buying More Shares In Corvus Pharmaceuticals
CRVS

Simply Wall St.

a year ago

Insider Spends US$1m Buying More Shares In Corvus Pharmaceuticals

CRVS

MT Newswires

a year ago

Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript
CRVS

Insider Monkey

a year ago

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript

CRVS

Thomson Reuters StreetEvents

a year ago

Q1 2024 Corvus Pharmaceuticals Inc Earnings Call

CRVS

GuruFocus.com

a year ago

Corvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...

CRVS

Associated Press Finance

a year ago

Corvus: Q1 Earnings Snapshot

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
CRVS

Zacks

a year ago

Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
CRVS

Zacks

a year ago

Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround

Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
CRVS

Zacks

a year ago

Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript
CRVS

Insider Monkey

a year ago

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript

CRVS

Thomson Reuters StreetEvents

a year ago

Q4 2023 Corvus Pharmaceuticals Inc Earnings Call

CRVS

Associated Press Finance

a year ago

Corvus: Q4 Earnings Snapshot

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully
CRVS

Simply Wall St.

a year ago

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully

Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
CRVS

Zacks

a year ago

Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

CRVS

Associated Press Finance

a year ago

Midland States Bancorp: Q4 Earnings Snapshot

USCB Financial Holdings, Inc. Reports Diluted EPS of $0.14 for Q4 2023
CRVS

GlobeNewswire

a year ago

USCB Financial Holdings, Inc. Reports Diluted EPS of $0.14 for Q4 2023

Midland States Bancorp, Inc. Announces 2023 Fourth Quarter Results
CRVS

GlobeNewswire

a year ago

Midland States Bancorp, Inc. Announces 2023 Fourth Quarter Results

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
CRVS

GlobeNewswire

a year ago

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
CRVS

Zacks

a year ago

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

Eagle Bancorp Montana Earns $2.2 Million, or 0.28 per Diluted Share, in the Fourth Quarter of 2023 and $10.1 Million, or $1.29 per Diluted Share, for the Year 2023
CRVS

GlobeNewswire

a year ago

Eagle Bancorp Montana Earns $2.2 Million, or 0.28 per Diluted Share, in the Fourth Quarter of 2023 and $10.1 Million, or $1.29 per Diluted Share, for the Year 2023

GALIANO GOLD REPORTS PRELIMINARY 2023 PRODUCTION RESULTS
CRVS

CNW Group

a year ago

GALIANO GOLD REPORTS PRELIMINARY 2023 PRODUCTION RESULTS

Syntec Optics (Nasdaq: OPTX) CEO Interviewed by New York Photonics Cluster
CRVS

GlobeNewswire

a year ago

Syntec Optics (Nasdaq: OPTX) CEO Interviewed by New York Photonics Cluster

Rigel Pharmaceuticals Provides Business Update
CRVS

PR Newswire

a year ago

Rigel Pharmaceuticals Provides Business Update

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
CRVS

PR Newswire

a year ago

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Individual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last week
CRVS

Simply Wall St.

a year ago

Individual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last week

Share on Social Networks: